203 related articles for article (PubMed ID: 26197747)
21. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
22. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management.
Shinagare AB; Howard SA; Krajewski KM; Zukotynski KA; Jagannathan JP; Ramaiya NH
AJR Am J Roentgenol; 2012 Dec; 199(6):1259-65. PubMed ID: 23169717
[TBL] [Abstract][Full Text] [Related]
23. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
24. Successfully treated pneumatosis cystoides intestinalis with pneumoperitoneum onset in a patient administered α-glucosidase inhibitor.
Tanabe S; Shirakawa Y; Takehara Y; Maeda N; Katsube R; Ohara T; Sakurama K; Noma K; Fujiwara T
Acta Med Okayama; 2013; 67(2):123-8. PubMed ID: 23603930
[TBL] [Abstract][Full Text] [Related]
25. [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].
Durand M; Logerot S; Fonrose X; Schir E
Therapie; 2014; 69(2):163-8. PubMed ID: 24926635
[TBL] [Abstract][Full Text] [Related]
26. Pneumatosis cystoides intestinalis with pneumoperitoneum and pneumoretroperitoneum following chemotherapy.
Kopp AF; Grönewäller E; Laniado M
Abdom Imaging; 1997; 22(4):395-7. PubMed ID: 9157858
[TBL] [Abstract][Full Text] [Related]
27. Pneumatosis Intestinalis After Molecular-Targeted Therapy.
Chaudhry NS; Bi WL; Gupta S; Keraliya A; Shimizu N; Chiocca EA
World Neurosurg; 2019 May; 125():312-315. PubMed ID: 30763745
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
29. [A case of pneumatosis cystoides intestinalis after neoadjuvant chemotherapy for esophageal cancer].
Akasaka H; Wajima N; Kimura A; Sakuraba S; Kubo N; Yamana D; Okano K; Ichinohe D; Shimada T; Hakamada K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2375-7. PubMed ID: 25731528
[TBL] [Abstract][Full Text] [Related]
30. Pneumatosis cystoides intestinalis associated with etoposide in hematological malignancies: a case report and a literature review.
Yang L; Zhong X; Yang H; Wu Q; Gong Y; Wang B
BMC Gastroenterol; 2022 Mar; 22(1):150. PubMed ID: 35346061
[TBL] [Abstract][Full Text] [Related]
31. Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Police A; Charre L; Volpin E; Antonopulos C; Braham H; El Arbi N
Int J Colorectal Dis; 2020 May; 35(5):943-946. PubMed ID: 32095873
[TBL] [Abstract][Full Text] [Related]
32. Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin.
Kung D; Ruan DT; Chan RK; Ericsson ML; Saund MS
Dig Dis Sci; 2008 Jan; 53(1):217-9. PubMed ID: 17530401
[TBL] [Abstract][Full Text] [Related]
33. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
[TBL] [Abstract][Full Text] [Related]
34. Pneumatosis Cystoides Intestinalis: A Case Report.
Ohata Y; Higuchi H; Ogawa S; Watari T
Am J Case Rep; 2023 Jan; 24():e938207. PubMed ID: 36694439
[TBL] [Abstract][Full Text] [Related]
35. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
36. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
[TBL] [Abstract][Full Text] [Related]
37. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
38. Pneumatosis cystoides intestinalis: an unusual cause of intestinal ischemia and pneumoperitoneum.
Ogul H; Pirimoglu B; Kisaoglu A; Karaca L; Havan N; Ozogul B; Kantarci M
Int Surg; 2015 Feb; 100(2):221-4. PubMed ID: 25692421
[TBL] [Abstract][Full Text] [Related]
39. Pneumatosis cystoides intestinalis: a complication of systemic chemotherapy.
Shindelman LE; Geller SA; Wisch N; Bauer JJ
Am J Gastroenterol; 1981 Apr; 75(4):270-4. PubMed ID: 7258172
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
